Last reviewed · How we verify

Sodium Ozagrel — Competitive Intelligence Brief

Sodium Ozagrel (Sodium Ozagrel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thromboxane A2 synthetase inhibitor. Area: Cardiovascular.

marketed Thromboxane A2 synthetase inhibitor Thromboxane A2 synthetase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Sodium Ozagrel (Sodium Ozagrel) — Tanabe Pharma Corporation. Sodium ozagrel inhibits thromboxane A2 synthetase, reducing platelet aggregation and thrombosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sodium Ozagrel TARGET Sodium Ozagrel Tanabe Pharma Corporation marketed Thromboxane A2 synthetase inhibitor Thromboxane A2 synthetase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thromboxane A2 synthetase inhibitor class)

  1. Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sodium Ozagrel — Competitive Intelligence Brief. https://druglandscape.com/ci/sodium-ozagrel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: